## **Todd Kremin**

From:

Robert Trumpy

Sent:

Thursday, July 27, 2006 4:55 PM

To:

'Matt Samuel'

Subject:

revised biosafe proj

Attachments: Retail proforma 07-27-06.xls

I looked at the expenses critically and increased several categories with the following logic. I now included those expenses that Biosafe would have incurred in running this level of revenue with the assumption that as of 8/1/06 expenses begin to increase with the new team gradually coming on board. The benefit of those added people will marginally be felt in 2006 and reach full value (ie. revenue increase) in 2007. The larger increase in expense for salaries/expenses in 2007 tracks with the increase in volume/revenue for 2007.

Call me if there are still concerns. As a reminder, the "going public" costs are not in any year per Andrews initial instructions.

Rob Trumpy, CPA SVP and CFO BioSafe Medical Technologies, Inc. 100 Field Drive, Suite 240 Lake Forest, IL 60045 Work:847-234-8111 Fax:847-234-8222 rtrumpy@ebiosafe.com

| Retail Newco | Projected Income Statement | INTERNAL USE ONLY - Confidential |
|--------------|----------------------------|----------------------------------|
|--------------|----------------------------|----------------------------------|

|  | INTERN   | AL USE                                  | INTERNAL USE ONLY - Confidential | nnfiden        | 90                                    |                           | 2007             |           | 2008              | 2009   |                     |
|--|----------|---|----------------------------------|----------------|---------------------------------------|---------------------------|------------------|-----------|-------------------|--|---------------------|
| Product Revenue  |          | 8                                       | (as II)                          |                |                                       |                           |                  |           |                   | e d'albanda de la compania de la co |                     |
| Cholestestol Panel   |          | <del>6</del> 7                          | 277.200                          | €9             | 450,450                               | €9                        | 1,145,375        | €9        | 1,617,000 \$      | 1,886,500  |                     |
| TSH  |          | ÷ €                                     | 255,906                          | <del>(4)</del> | 471,192                               | €9                        | 1,218,600        | ↔         |                   |  |                     |
| PSA  |          | ↔                                       | 357,000                          | ↔              | 541,875                               | €9                        | 1,083,750        | ⇔         |                   | <del>-</del>   |                     |
| Hemoalobin A1c   |          | <del>69</del>                           | 10,360                           | ÷              | 77,700                                | ᢒ                         | 691,530          | so.       | \$ 008'669        |  |                     |
| Disease Management-Pharmacy                                  |          | €9                                      | 552,300                          | €              | 437,238                               | 69                        | 1,288,700        | ↔         |                   | 2  |                     |
| Anemia Meter   |          |   | 4,185                            |                | 209,250                               |                           | 781,200          |           | 837,000           | 627,750  |                     |
| Rapid Allergy  |          |   | . 1                              |                | •                                     |                           | 1,276,800        |           | 2,394,000         | 2,992,500  |                     |
| New Development  |          |   | 1                                |                | 1                                     |                           | ı                |           | 1,871,250         | 3,742,500  |                     |
| Internet   |          |   | 125,887                          |                | 455,289                               |                           | 865,123          |           | 1,038,148         | 1,245,777  |                     |
| Bavenue vis Acquisifion                                      |          |   |                                  |                |                                       |                           |                  |           |                   |  |                     |
| Total Revenue  |          |   | 1,582,838                        |                | 2,642,994                             | NAME OF TAXABLE PARTY.    | 8,351,078        |           | 13,604,638        | 17,929,327   |                     |
| COGS-Blosafe Products  |          | G                                       | 674,552                          | ₩              | 957,206                               | €                         | 3,123,325        | ₩.        | 4,825,089 \$      | 6,386,897  |                     |
| COGS via Acquisition   |          |   | •                                | ₩              | r                                     | <del>49</del>             |                  | <b>69</b> | <b>€</b>          |  |                     |
| Royalty to Biosafe   | %8       | \$                                      | 126,627                          | s              | 211,439                               | 49                        |                  | s         | -                 |  |                     |
| Total Gross Margin<br>% of Net Revenue                       |          |   | 781,659<br>49%                   |                | 1,474,348<br>56%                      |                           | 4,559,667<br>55% |           | 7,691,178<br>57%  | 10,108,084<br>56%  |                     |
| Selling, General and Administrative (non-public assumptions) | dud-non) | lic ass                                 | umptions)                        |                | 52,860                                |                           | 167.022          |           | 272,093           | 358,587  |                     |
| Other Salaries   | 2        |   | 2                                |                | 150,000                               |                           | 570,000          |           | 650,000           | 730,000  |                     |
| Interim Services from Biosafe                                |          |   |                                  |                | 25,000                                |                           | •                |           |                   |  |                     |
| Rent/Utilities   |          |   |                                  |                | 50,000                                |                           | 120,000          |           | 120,000           | 180,000  |                     |
| Payroll Tax & Benefits                                       |          |   | 5,540                            |                | 35,500                                |                           | 128,979          |           | 161,366           | 190,503  |                     |
| Professional   |          |   |                                  |                | 25,000                                |                           | 75,000           |           | 81,000            | 87,480   |                     |
| General Insurance  | è        |   | 1                                |                | 10,000                                |                           | 30,000           |           | 40,000<br>136,048 | 45,000   |                     |
| Bad Debt @   | <u>%</u> |   | 15,828                           |                | 23,930                                |                           | 78.083           |           | 120,627           | 159,672  |                     |
| Ottlet Experises<br>Advertising/Marketing                    | 4%       |   |                                  |                | 26,430                                |                           | 334,043          |           | 544,186           | 717,173  |                     |
| Travel & Entertainment                                       | 2        |   |                                  |                | 10,000                                |                           | 35,000           |           | 40,000            | 75,000   |                     |
| Total S,G & A  |          |   | 53,025                           |                | 435,150                               |                           | 1,621,637        |           | 2,165,318         | 2,722,708  |                     |
| EBITDA   |          |   | 728,634                          |                | 1,039,198                             |                           | 2,938,030        |           | 5,525,860         | 7,385,376  |                     |
| % of Revenue   |          |   | 46%                              |                | 39%                                   |                           | 35%              |           | 41%               | 41%  |                     |
| Depreciation and Amortization                                |          |   | ı                                |                | 220,000                               |                           | 265,000          |           | 315,000           | 370,000  |                     |
| EBIT   |          |   | 728,634                          |                | 819,198                               |                           | 2,673,030        |           | 5,210,860         | 7,015,376  |                     |
| % of Revenue   |          |   | 46%                              |                | 31%                                   |                           | 32%              |           | 38%               | 0/.85°   |                     |
| Interest Income  |          |   | 12,000                           |                | 1                                     |                           | 57,912           |           | 10,481            | 28,218   |                     |
| interest<br>Pre Tax Profit (Loss)                            |          | *************************************** | 740,634                          |                | 819,198                               |                           | 2,730,942        |           | 5,221,341         | 7,043,594  |                     |
| Income Taxes   |          |   | 277,738                          |                | 307,199                               | - ALEXANDER OF THE STREET | 1,024,103        |           | 1,958,003         | 2,641,348  |                     |
| Net Income<br>ะกเชิงlof Revenue                              |          |   | 462,896<br>29M⊺                  | ERNA           | 2.896 DII,999<br>29MTERNAL USE 1911 Y | ,                         | 20%              |           | 24%               | 25%  | 25%/28/200811:46 AM |
|  |          |   |                                  |                |                                       |                           |                  |           |                   |  |                     |

Confidentifalof Revenue

4/28/200811:46 AM

INTERNAL USE ONLY

| Projected Balance Sheet  | Sheet INTERNAL USE ONLY                              | 2005 | 2006       | 2007        | 2008        | 2009                                    |
|--|--|------|------------|-------------|-------------|---|
| Assets   |  |      | 1          |             | 740 004     | 0 110 600                               |
|  | Cash   |      | 7,680,084  | 524,013     | 1,410,901   | 3,140,032                               |
|  | Accounts Receivable (net of allowance)               |      | 3/7/5/1    | 1,193,011   | 1,943,520   | 2,56,196,2                              |
|  | Inventories  |      | 100,000    | 200,000     | 250,000     | 2,400,000                               |
|  | Prepaid Expenses                                     |      | 10,000     | 10,000      | 10,000      | 10,000                                  |
|  | Total Current Assets                                 |      | 3,383,165  | 1,927,084   | 3,614,421   | 8,711,965                               |
|  | Property, Equip & Cap Devl Costs, net                | 0    | 80,000     | 80,000      | 95,000      | 120,000                                 |
|  | Goodwill   |      | 4,000,000  | 4,000,000   | 4,000,000   | 4,000,000                               |
|  | Product Licenses                                     | 0    | 4,800,000  | 5,560,000   | 6,280,000   | 6,960,000                               |
| in the second se | Total Assets   | 0    | 12,263,165 | 11,567,084  | 13,989,421  | 19,791,965                              |
| Lanings  | A/P Trade  |      | 121,166    | 348,247     | 517,246     | 677,543                                 |
|  | Payroll and Payroll Taxes                            |      | 100,000    | 140,000     | 150,000     | 160,000                                 |
|  | Compliance Accrual                                   |      | 30,000     | 000'09      | 000'06      | 120,000                                 |
|  | Notes Payable - Current<br>Total Current Liabilities | 0    | 251,166    | 548,247     | 757,246     | 957,543                                 |
|  |  |      |            |             |             |   |
|  | Other Long Term Liabilities                          |      | ţ          | 6           | COCC CAR    | 000000000000000000000000000000000000000 |
|  | Notes Payable - Long Term                            |      | 0          | (2,700,000) | (3,750,000) | (2,550,000)                             |
|  | Total Liabilities                                    | 0    | 251,166    | (2,151,753) | (2,992,754) | (1,592,457)                             |
| Shareholders Equity  | ţ,   |      |            |             |             |   |
| •  | Common Stock   | 0    | 11,500,000 | 11,500,000  | 11,500,000  | 11,500,000                              |
|  | Beg Retained Earnings                                | 0    | 0          | 511,999     | 2,218,837   | 5,482,175                               |
|  | Current Period Income(Loss)                          |      | 511,999    | 1,706,838   | 3,263,338   | 4,402,246                               |
|  | Ending Retained Earnings                             | 0    | 511,999    | 2,218,837   | 5,482,175   | 9,884,422                               |
|  | Total Stockholders Equity                            | 0    | 12,011,999 | 13,718,837  | 16,982,175  | 21,384,422                              |
| Total Liabilities and  | Total Liabilities and Stockholdere Equip             | C    | 12,263,165 | 11.567.084  | 13.989.421  | 19.791.965                              |

| - 0000 1.07 07 11100 0010 | Case 1:07-cv-11135-JSR | Document 16-38 | Filed 05/01/2008 | Page 5 of 8 |
|---------------------------|------------------------|----------------|------------------|-------------|
|---------------------------|------------------------|----------------|------------------|-------------|

| Newco Retail<br>Projected Statement   | of Gash Flow  | Newco Retail Projected Statement of Cash Flow INTERNAL USE ONLY                        | Annual<br>2005                            | Annual<br>2006                                  | Annual<br>2007                                   | Arriual 2008                                     | Arinual<br>2009                                  |
|---|---|--|---|---|--|--|--|
| Beg. Cash and Rese  | Beg. Cash and Reserve for Future Development  | ment   |   | 0   | 2,895,594  | 524,073  | 1,410,901  |
| Net income (loss)   | :   |  |   | 511,999   | 1,706,838  | 3,263,338  | 4,402,246  |
| Change in working capital (less cash):<br>Current assets<br>Current liabilities                             | pital (less cash):  |  | 0   | (487,571)<br>251,166                            | (915,441)<br>297,080                             | (800,509)<br>208,999                             | (2,767,813)<br>200,297                           |
| Depreciation/Amortization<br>Net PPE decrease (increa   | Depreciation/Amortization<br>Net PPE decrease (increase) including capitalized R & D  | lized R & D  | 0   | 220,000<br>(5,100,000)                          | 265,000<br>(1,025,000)                           | 315,000<br>(1,050,000)                           | 370,000<br>(1,075,000)                           |
| Goodwill purchase<br>Issue of Note Payable for License<br>Repayment of Note Payable                         | for License<br>ayable   |  |   | (4,000,000)<br>2,500,000<br>(2,500,000)         | (2,700,000)                                      | (1,050,000)                                      | 2,000,000 (800,000)                              |
| Increase other long term liability issuance of common stock, net of fees Ending Cash and Reserve for Future | Increase other long term liability<br>Issuance of common stock, net of fees<br>Ending Cash and Reserve for Future Development | opment   | 0   | 11,500,000<br><b>2,895,594</b>                  | 0<br><b>524,073</b>                              | 0<br><b>1,410,90</b> 1                           | 0<br>3,740,632                                   |
|   |   |  | 0   | 0   | 0  | 0  | 0  |
| Projected Long Term   | Projected Long Term Asset/Liability Work Schedule INTERNAL USE ONLY Confidential  | Scheduile<br>Confidential  | Arinual<br>2005                           | Annual<br>2006                                  | Annual<br>2007                                   | Annual<br>2008                                   | Annual<br>2009                                   |
|   | Fixed Assets  | Beginning Balance<br>Depreciation/Amort.<br>Purchases/Cap R&D<br><b>Ending Balance</b> | 0   | (20,000)<br>100,000<br><b>80,000</b>            | 80,000<br>(25,000)<br>25,000<br>80,000           | 80,000<br>(35,000)<br>50,000<br>95,000           | 95,000<br>(50,000)<br>75,000<br>120,000          |
|   | License<br>Amort years 25   | Beg. Balance<br>Amortization<br>New licenses<br>Ending Balance                         | 0   | 0<br>(200,000)<br>5,000,000<br><b>4,800,000</b> | 4,800,000<br>(240,000)<br>1,000,000<br>5,560,000 | 5,560,000<br>(280,000)<br>1,000,000<br>6,280,000 | 6,280,000<br>(320,000)<br>1,000,000<br>6,960,000 |
| Projected Capitalization Table  |   | INTERNAL USE ONLY<br>Confidential  | Annual<br>2005                            | Annual<br>2006                                  | Annual<br>2007                                   | Annual<br>2008                                   | Annual<br>2009                                   |
|   | Beginning Shares Issued/Outstanding   | ed/Outstanding   |   | 0   | 12,166,666                                       | 12,166,666                                       | 12,166,666                                       |
|   | Shares Issued During Period # Ending Share Count  | Period = #   | 0   | 12,166,666                                      | 12,166,666                                       | 12,166,666                                       | 12,166,666                                       |
|   | Beginning \$ Value at Issued Price Shares Issued During Period - \$ 2,500,000 @ \$ 1 5,000,000 @ \$ 1                         | sued Price<br>Period - \$<br>\$ 1.00<br>\$ 1.00  |   | 0<br>2,500,000<br>5,000,000                     | 12,000,000                                       | 12,000,000                                       | 12,000,000                                       |
| Confidential  | 7,500,000 @ \$ 500,000 @ \$ 2,666,666 \$ Ending \$ Value at issued Price  | \$ 1.00<br>\$ 1.50   | INTERNAL USE ONLY,500,000<br>0 12,000,000 | ONLX500,000<br>4,000,000<br>12,000,000          | 12,000,000                                       | 12,000,000                                       | 4/28/200811:46 AM<br><b>12,000,000</b>           |

|   |  |  | Send-in  |   |  | - AND  | Rapid tests  | Total  |       |
|---|--|--|--|---|--|--|--|--|-------|
| ;   | Cholestestol   | TSH  | PSA  | bin   | langt  | Anemia Meter R   | Rapid Allergy  | New<br>Development   |       |
|   | Panel  |  |  | A1c   | NIS  |  |  |  |       |
| Stores  | 2.400  | 4.200  | 4,200  | 200   | 750  | 100  |  |  |       |
| Kits per Store/vear   | 9  | )<br>1   | 4  | *   | 80   | င  |  |  | С     |
| •   | 14,400   | 12,600   | 16,800   | 800   | 000'09   | 300  | ,  | •  | as    |
|   | 10.05  | 20.34  | 2125 \$  | 12.95   | 9.21   | 13,95  |  |  | е     |
| Revenue 2005  | \$ 277,200 \$  | 255,906 \$   | 357,000 \$   | -   |  | 4,185 \$   | ·  | - \$ 1,456,951   | 1:0   |
| COGS 2005   | 98,525   | 101,836  | 126,865 \$   | 4,523   | 316,800  | 825 \$   | AND THE CONTRACTOR OF T  | ŧ.   | 07-   |
| 180 C | The state of the s | оможно водинати в при водинати в при водинати во | A PART OF THE PART | OUR HINDOMSON AND MAIN AND AND AND AND AND AND AND AND AND AN | CONTRACTOR OF A CANADA STATEMENT OF A CANADA | ANAMANANANANANANANANANANANANANANANANANA  |  | wassermentelebilisteristeristeristeristeristeristerister   | ·CV-  |
| Stores  | 3,900  | 5,800  | 5,100  | 1,200   | 1,900<br>25  | 2,500<br>6   |  |  | -11   |
| Kits per Store/year   | 23,400   | 23,200   | 25,500   | 6,000   | 47,500   | 15,000   | ,  | •  | 113   |
|   | 4<br>10 07 6   | 20.31  | 21 25 A  | 12.95.  | 9.21 \$  | 13.95  |  |  | 35-   |
|   | i  | 47   | 1  | 77,700  | 437,238  | 209,250 \$   | ъ.   | - \$ 2,187,705   | JS    |
| 2006  |  | 187,508  | 192,563 \$   | 33,924 \$   | 250,800  | 41,250 \$  | ,  | - 1  | SR    |
|   |  |  | D. W. C.   | MON   | NOVERESTREET, THE PARTY OF THE  |  |  |  |       |
| Stores  | 8,500  | 10,000   | 8,500  | 8,900   | 3,500  | 14,000   | 8,000  | ;  | D     |
| Kits per Store/year   | 7  | \$   | 9  | 9 00  | 40   | 4  | 84 000   | £ .  | oc    |
|   | 59,500   | 60,000   | 51,000   | 53,400  | 140,000  | 000,000  | 5  |  | ur    |
| Unit Price  |  | 20.31  |  | 12.95   | 9.21 \$  | 13.95 \$   | - 1  | Į  | ne    |
| Revenue   | 1,14   | 1,21   | 1,083,750 \$   | 691,530   | 1,288,700  | 1  |  | - \$ 7,485,955   | nt    |
|   | 407,099  | 484,935 \$   | 1  | 301,924 \$  | 739,200 \$   | 154,000 \$   | 478,016 \$   | -  | : 1   |
|   |  |  |  |   |  | and the control of the second  |  |  | 6-3   |
| Stores  | 12,000   | 14,000   | 14,000   | 000'6   | 4,500  | 15,000   | 15,000   | 7,500  | 8     |
| Kits per Store/year   | 7  | 9  | 9 000  | 9 000   | 180 000  | 80 000   | 120 000  | 75.000   |       |
|   | 04,000   | 04,000   | 200,10   |   |  |  |  |  | F     |
| Unit Price  |  | 20.31  | - 1  |   | 9.21 \$  |  | - !  |  | ile   |
| Revenue 2008  | 1,617,000  | 1  | 1,785,000 \$   | 699,300 \$  | 1,656,900 \$   | 837,000 \$   | 2,394,000 \$   | 412.500 \$ 12,000,450  | d     |
| COGS 2008   | \$ 574,728 \$  | \$ 606'879   | 634,326 \$   | ı.  | 1  | 1  |  |  | 05    |
| 6007  |  | W. Die Service Control of the Contro |  | 111111111111111111111111111111111111111                       | STEEN STATE OF THE PARTY OF THE | A STATE OF THE PROPERTY OF THE | and a state of the | A CONTRACTOR OF THE PROPERTY O | 5/0   |
|   | 14,000   | 15,000   | 15,000   | 12,000  | 10,000   | 15,000   | 15,000   | 15,000   | 1/:   |
| Kits per Store/year   | 000'86   | 000'06   | 000'06   | 72,000  | 300,000  | 45,000   | 150,000  | 150,000  | 200   |
|   | 10.05.   | 20.31  | 21.25  | 12.95   | 9.21   | 13.95 \$   | 19.95 \$   |  | 8     |
| Dovernia Davernia   | 1.886.500  | 1.827.900 \$   | 1  | 932,400   |  |  | 2,992,500 \$   | 3,742,500 \$ 16,683,550  |       |
| COGS 2009   | \$ 670,516 \$  | -  | 679,635 \$   | 407,088   | 1,584,000  | 1 1  | 1,120,350 \$   |  | Pa    |
|   | Cholesterol<br>Panel   | TSH  | PSA  | Hemoglobin<br>A1c   | Disease<br>Management  | Anemia R   | Rapid Allergy<br>De  | New<br>Development   | age 6 |
| Cost of Goods Sold:   |  |  |  |   |  |  |  |  | of    |
| Office Codes.<br>Kits (& outbound shipping)   | 2.00   | 3.95   | 1.20   | 1.49  | 1.95   | 2.50   | 6.79   | 5.00   | 8     |
| et of non-compliar  | 4.22   | 3.40   | 5.67   | 3.65  | 2.85   | 0.25   | 0 68   | 0.50   |       |
| Outsource Vendor Markup<br>Total Unit Cost  |  | 0.73<br>8.08   | 7.55   | 5.65  | 5.28   | 2.75   | 7.47   | 5.50   |       |
| Wholesale price   | \$ 19.25 \$  | 20.31 \$   | 21.25 \$   | 12.95 \$  | 9.21 \$  | 13.95 \$   | 19.95 \$   | 16.85  |       |
| Gross Margin %  | 64%  | %09  | 64%  | 99%   | 43%  | 80%  | 63%  | 0/./0  |       |
|   |  |  |  |   |  |  |  |  |       |

Volume, Pricing and COGS

Newco Retail

## Newco Retail **Employee Listing**

| Position         | 2005         | 2006    | 2007    | 2008    |
|------------------|--------------|---------|---------|---------|
| President        |              | 50.000  | 000 000 |         |
|                  |              | 50,000  | 200,000 | 200,000 |
| Chief Accountant |              |         | 75,000  | 75,000  |
| VP Sales         |              |         | 135,000 | 135,000 |
| Brand Manager(s) |              | 80,000  | 80,000  | 160,000 |
| Sales Assistant  |              | 20,000  | 45,000  | 45,000  |
| Admin            |              |         | 35,000  | 35,000  |
| Total            | <del>-</del> | 150,000 | 570,000 | 650,000 |

| 2009    |
|---------|
|         |
| 200,000 |
| 75,000  |
| 135,000 |
| 240,000 |
| 45,000  |
| 35,000  |
| 730,000 |